Patients are at the heart of everything we do at Loxo Oncology, and we continue to be motivated by one goal: to dramatically improve the lives of people living with cancer by developing medicines against genetically defined targets driving cancer growth. Though drug development can be risky and complicated, we work hard to navigate through these complexities for the benefit of patients.
Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.
Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.
From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.
Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.
Jacob S. Van Naarden serves as Chief Business Officer. In his previous roles, Mr. Van Naarden served in various biotechnology investing, operating, and advisory capacities.
Previously, Mr. Van Naarden served as a public equity biotechnology analyst at HealthCor Management, a multi-billion dollar healthcare-dedicated investment firm based in NYC. Prior to HealthCor, Mr. Van Naarden was an Associate at Aisling Capital, a multi-strategy healthcare investment firm based in NY. Mr. Van Naarden started his career in the Healthcare Group of the Investment Banking Division at Goldman Sachs.
Mr. Van Naarden received his A.B. degree in molecular biology from Princeton University, graduating magna cum laude and Phi Beta Kappa.
Jennifer Burstein, C.P.A., serves as VP of Finance.
Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance.
Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting.
Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.
Dr. Nanda serves as Senior Vice President of Development Strategy. Dr. Nanda has had increasing roles of responsibility in both clinical and pre-clinical development. Most recently Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo).
Dr. Nanda’s career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and Cor.
Dr. Nanda has a BSc Hons in Biochemistry and Molecular Genetics from UNSW, Sydney, Australia and a PhD in Biochemistry and Molecular Genetics from UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia.
Sara Slifka serves as Vice President of Business Operations and Program Management. Previously, Ms. Slifka was a Vice President in Equity Research at Morgan Stanley covering the biotech sector.
In her prior role, Ms. Slifka analyzed small and large cap biotechnology companies from a financial, clinical, regulatory and commercial perspective.
Ms. Slifka received her A.B. degree from Princeton University.
Dr. S. Michael Rothenberg, M.D., Ph.D., serves as Vice President of Research and Development.
Previously, Dr. Rothenberg was a medical oncologist and cancer researcher at Massachusetts General Hospital.
Dr. Rothenberg trained at Massachusetts General Hospital in internal medicine and at the Massachusetts General Hospital Cancer Center and the Dana Farber Cancer Institute in medical oncology, earning board certification in these specialties. He received his M.D. and Ph.D. degrees from the Stanford University School of Medicine, and his B.A. degree in Chemistry from Yale University.
Dr. Nora Ku, M.D., serves as a Senior Medical Director for Loxo Oncology.
Her career in academic and community practice included active involvement in clinical research as a clinical investigator. Prior to joining Loxo Oncology Dr. Ku worked with a specialty consulting group supporting projects facilitating drug development by large and small pharmaceutical company clients.
Dr. Ku is a graduate of the UCLA School of Medicine. She completed her residency in Internal Medicine at UT Southwestern Medical Center and returned to UCLA to complete a combined fellowship in Hematology and Oncology. She is board certified in Internal Medicine and Medical Oncology.
Dr. Deborah Morosini, M.D., M.S.W., serves as Vice President of Clinical Affairs and Patient Engagement.
Previously, Dr. Morosini was a VP at Foundation Medicine, a cancer genomics and molecular information company in Cambridge, MA. From 2007-2012, Dr. Morosini led the molecular pathology group at AstraZeneca Pharmaceuticals.
She is a seasoned patient advocate, serving on multiple national non-profit boards.
Dr. Morosini trained at Boston University School of Medicine in anatomic and clinical pathology, where she served as chief resident. She received her M.D. from Boston University School of Medicine, her Masters in Social Work from New York University and her BA in English from Mount Holyoke College.
Katie Cairati serves as Executive Director, Global Regulatory Affairs. Ms. Cairati’s career spans many aspects of drug development including regulatory affairs, clinical development, data management and manufacturing.
Previously Ms. Cairati has held increasing roles of responsibility at Genentech, Pharmacyclics and ChemGenex in addition to establishing her own consulting firm, Cairati Consulting Inc.
Ms. Cairati received her MS degree from University of California, Davis.
Dr. Michael Cox, Pharm.D., serves as Senior Director, Clinical Development and Medical Affairs. Dr Cox has been involved in the product launches and life cycle management of numerous oncology products including radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®) cetuximab (Erbitux®), denosumab (XGEVA®) and darbepoetin alfa (Aranesp®).
Dr. Cox joined Loxo Oncology from Bayer Consumer Care AG, Basel, Switzerland where he served as Medical Affairs Early Pipeline Lead, Oncology for Region Europe/Canada and Emerging Markets. Prior to Bayer, he held global medical affairs positions at Merck KGaA, Darmstadt, Germany and Amgen, Inc., Thousand Oaks, California.
Dr. Cox received his Pharm.D. from Ohio Northern University and a MHSc in Clinical Research from Duke Unviersity’s School of Medicine. Dr. Cox completed pharmacy practice residencies at Mission Hospitals in Asheville, North Carolina and the University of Pittsburgh Cancer Institute – University of Pittsburgh Medical Cancer, Pittsburgh, Pennsylvania. He completed a medical oncology/clinical drug development fellowship in the Clinical Pharmacology Section, Center for Cancer Research at the National Cancer Institute, Bethesda, Maryland. He is a Board Certified Oncology Pharmacist.